High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy

World Journal of Surgical Oncology

Minshan Chen¹  Jianchuan Xia¹  Ke Pan¹  Yaojun Zhang¹  Shanshan Jiang¹  Haoyuan Wang¹ 

[1] State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

关键词: prognostic factor;    prognosis;    hepatectomy;    hepatocellular carcinoma;    thymosin beta 10;   

Others  :  1148588
DOI  :  10.1186/1477-7819-12-226

 received in 2014-03-17, accepted in 2014-07-04,  发布年份 2014

【 摘 要 】

Background

Thymosin beta 10 (Tbeta10) overexpression has been reported in a variety of human cancers. However, the role of Tbeta10 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to analyze Tbeta10 expression in tumor and matched non-tumorous tissues, and to assess its prognostic significance for HCC after hepatectomy.

Methods

The level of Tbeta10 mRNA and protein in tumor and matched non-tumorous tissues was evaluated in 26 fresh HCC cases by reverse transcription-polymerase chain reaction (RT-PCR) and western blot. Additionally, Tbeta10 protein expression in 196 HCC was analyzed by immunohistochemistry (IHC) and correlated with clinicopathological characteristics and survival.

Results

Results from RT-PCR and western blot analysis show that the levels of Tbeta10 mRNA and protein were significantly higher in tumor tissues of HCC, compared to that in matched non-tumorous tissues (P = 0.01 and P <0.001, respectively). IHC staining showed that high expression of Tbeta10 was detected in 58.2% (114/196) of HCC cases. High expression of Tbeta10 was significantly associated with advanced TNM stage (P <0.001). Survival analysis demonstrated that high Tbeta10 was related to shorter overall survival (OS) (P = 0.000) and disease-free survival (DFS) (P = 0.000). Multivariate analysis showed that high expression of Tbeta10 was an independent prognostic factor for both OS (P = 0.001, HR = 4.135, 95% CI: 2.603 to 6.569) and DFS (P = 0.001, HR = 2.021, 95% CI: 1.442 to 2.832). Subgroup analysis revealed that high expression of Tbeta10 predicts poorer survival for early and advanced stage.

Conclusions

Tbeta10 protein abnormal expression might contribute to the malignant progression of HCC. High expression of Tbeta10 predicts poor prognosis in patients with HCC after hepatectomy.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56:908-943.
• [3]Bruix J, Boix L, Sala M, Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219.
• [4]Goldstein AL, Slater FD, White A: Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci U S A 1966, 56:1010-1017.
• [5]Yu FX, Lin SC, Morrison-Bogorad M, Atkinson MA, Yin HL: Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem 1993, 268:502-509.
• [6]Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q: Roles of thymosins in cancers and other organ systems. World J Surg 2005, 29:264-270.
• [7]Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C: Advances in thymosin beta10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest 2009, 27:1016-1022.
• [8]Sribenja S, Wongkham S, Wongkham C, Yao Q, Chen C: Roles and mechanisms of beta-thymosins in cell migration and cancer metastasis: an update. Cancer Invest 2013, 31:103-110.
• [9]Califano D, Monaco C, Santelli G, Giuliano A, Veronese ML, Berlingieri MT, de Franciscis V, Berger N, Trapasso F, Santoro M, Viglietto G, Fusco A: Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res 1998, 58:823-828.
• [10]Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N: Quantitative analysis of thymosin beta-10 messenger RNA in thyroid carcinomas. Jpn J Clin Oncol 2002, 32:229-232.
• [11]Weterman MA, van Muijen GN, Ruiter DJ, Bloemers HP: Thymosin beta-10 expression in melanoma cell lines and melanocytic lesions: a new progression marker for human cutaneous melanoma. Int J Cancer 1993, 53:278-284.
• [12]Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, Wang HY: Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer 2011, 117:3363-3373.
• [13]Theunissen W, Fanni D, Nemolato S, Di Felice E, Cabras T, Gerosa C, Van Eyken P, Messana I, Castagnola M, Faa G: Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. Eur J Histochem 2014, 58:2242.
• [14]Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
• [15]Liu CR, Ma CS, Ning JY, You JF, Liao SL, Zheng J: Differential thymosin beta 10 expression levels and actin filament organization in tumor cell lines with different metastatic potential. Chin Med J (Engl) 2004, 117:213-218.
• [16]Oien KA, Vass JK, Downie I, Fullarton G, Keith WN: Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene 2003, 22:4287-4300.
• [17]Verghese-Nikolakaki S, Apostolikas N, Livaniou E, Ithakissios DS, Evangelatos GP: Preliminary findings on the expression of thymosin beta-10 in human breast cancer. Br J Cancer 1996, 74:1441-1444.
• [18]Hall AK: Amplification-independent overexpression of thymosin beta-10 mRNA in human renal cell carcinoma. Ren Fail 1994, 16:243-254.
• [19]Hall AK: Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer 1991, 48:672-677.
• [20]Sribenja S, Sawanyawisuth K, Kraiklang R, Wongkham C, Vaeteewoottacharn K, Obchoei S, Yao Q, Wongkham S, Chen C: Suppression of thymosin beta10 increases cell migration and metastasis of cholangiocarcinoma. BMC Cancer 2013, 13:430.
• [21]Gu Y, Wang C, Wang Y, Qiu X, Wang E: Expression of thymosin beta10 and its role in non-small cell lung cancer. Hum Pathol 2009, 40:117-124.
• [22]Lee SH, Zhang W, Choi JJ, Cho YS, Oh SH, Kim JW, Hu L, Xu J, Liu J, Lee JH: Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis. Oncogene 2001, 20:6700-6706.
• [23]McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M: Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002, 8:1127-1138.
• [24]Santelli G, Califano D, Chiappetta G, Vento MT, Bartoli PC, Zullo F, Trapasso F, Viglietto G, Fusco A: Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol 1999, 155:799-804.
• [25]Hall AK: Thymosin beta-10 accelerates apoptosis. Cell Mol Biol Res 1995, 41:167-180.
• [26]Li M, Zhang Y, Zhai Q, Feurino LW, Fisher WE, Chen C, Yao Q: Thymosin beta-10 is aberrantly expressed in pancreatic cancer and induces JNK activation. Cancer Invest 2009, 27:251-256.
• [27]Feher LZ, Pocsay G, Krenacs L, Zvara A, Bagdi E, Pocsay R, Lukacs G, Gyory F, Gazdag A, Tarko E, Puskas LG: Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas. Pathol Oncol Res 2012, 18:449-458.
• [28]Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM: Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 2011, 74:1002-1014.
• [29]Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
• [30]Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005, 40:225-235.